CROHN'S/ UC REFERRAL FORM

E-prescribe the Fast & Easy way: select BioPlus from your EHR! Fax: 800-269-5493

Phone: 888-292-0744

A Careton C	company								piopius	srx.com	
PATIENT INFOR	MATION										
Patient's Name:					SSN:			DOB:			
Address:				City:			State:	,	Zip:		
Home Phone: Cell:				Height:	Height: Weight		'	Gender: Male F		Female	
Email					Diagnosis Code:						
INSURANCE IN	FORMATION (or at	tach co	py of the cards)								
Primary Insurance:			Policy Holder:	Rela	ationship:	Po	olicy #:		Group #:		
Secondary Insurance	e:		Policy Holder:	Rela	ationship:	Po	olicy #:		Group #:		
PRESCRIPTION	INFORMATION (for	IV med	ication attach a copy of	the pres	cription)						
AMJEVITA™ (adalimumab-atto) □ SureClick 40 mg/0.8 mL □ Prefilled Syringe 20 mg/0.4 mL □ Prefilled Syringe 40 mg/0.8 mL Induction: □ 160 mg SubQ Day 1 □ 4 x 40 mg SubQ in one day □ 2 x 40 mg SubQ per day for two consecutive days □ 2 x 40 mg SubQ Day 15 Qty: 6 Maintenance: □ 40 mg SubQ every other week					SIMPONI® (golimumab) □ Prefilled Syringe □ Autoinjector □ Induction: 200 mg (2 x 100 mg) SubQ at week 0 Qty: 2 syringes Refills: 0 SKYRIZI™ (risankizumab-rzaa) □ OBI □ VIAL □ Induction: 600 mg intravenously weeks 0, 4, 8						
Qty: Refills: CIMZIA®(certolizumab pegol) Prefilled Syringe					Qty: 1 Maintenance: □ 180 mg SubQ week12, then every 8 weeks □ 360 mg SubQ week12, then every 8 weeks Qty:1 STELARA® (ustekinumab)						
□ 200 mg SubQ every 2 weeks Qty: 28 day supply CUPIXENT® (dupilumab) □ Prefilled Syringe □ Pen					☐ IV Induction: ☐ 260 mg (pt weight: ≤ 55 kg) ☐ 390 mg (pt weight: 56-85 kg) ☐ 520 mg (pt weight: >85 kg) ☐ Qty: ☐ Refills: 0 ☐ Maintenance: Starting 8 weeks after IV induction dose, 90 mg SubQ every 8 weeks Qty: 1						
☐ Inject 300 mg SubQ every week Qty: 4 for 28 days Entocort® (budesonide)					SOLESTA® (dextranomer and sodium hyaluronate) 1 ml Prefilled Syringe 4 submucosal injections Qty: 4 Refills:						
a mg capsules □ 9 mg PO daily Qty: 90 HUMIRA® (adalimuma	Refil	lls:		Qty: 4 UCERIS □ 9 mg F Qty: 30	® (<i>budesonide</i>) 9 PO daily	mg Extended-Re					
□ Pen □ Prefilled Syringe □ Citrate Free (CF) □ Original Formula Induction: □ 160 mg SubQ day 1, 80 mg SubQ day 15 □ 80 mg SubQ day 1, 80 mg SubQ day 2/ 80 mg SubQ day 15 Qty: 1 pack Refills: 0					XELJANZ® (tofacitinib) ☐ Induction: 10 mg PO twice daily for 8-16 week Qty: ☐ Refills:						
Maintenance: □ 40 mg SubQ every other week Qty: 28 day supply Refills: □ ** If dosage form is not selected, PENS will be dispensed.** OMVOH™ (minikizumab-mrkz) □ Vial 20 mg/mL □ Prefilled Syringe 100 mg/mL □ N Induction: Inject 300 mg IV at weeks 0, 4, 8					XIFAXAN® (rifaximin) □ 200 mg tablet □ 550 mg tablet □ 550 mg PO three times per day for 14 days □ 200 mg PO three times per day for 16 days □ mg POtimes per day for days Qty: Refills: □						
Qty: 1 Refills: 2 Maintenance: □ 2 x 100 mg SubQ weeks 12 and every 4 weeks Qty: 2 Prefilled Syringes Refills: □ RINVOQ® (upadacitinib) extended-release tablets 15 mg □ 30 mg □ 45 mg □ 15 mg PO once daily for 8 weeks □ 45 mg PO once daily for 12 weeks □ 45 mg PO once daily for 8 weeks □ 45 mg PO once daily for 12 weeks □ 45 mg PO once daily for 8 weeks □ 45 mg PO once daily for 12 weeks □ Maintenance: mg once daily Qty: □ Refills: □					ZEPOSIA® (ozanimod)						
MMUNOSUPPRE AVSOLA® Initial Dose:	SSIVE INFUSION 🗆 E — ENTYVIO® mg/kg at w	imab	nab □ REMICADE® □ RENFLEXIS®mg/kg every 8 weeks								
OTHER	STRENGTH:	SIG/DI	RECTIONS:				REFILLS:	QUA	ANTITY:		
required by your state, Prescriber to check "Dispense as written" or handwrite "Brand Medically Necessary" d sign to prevent generic substitution.											
PHYSICIAN INFO	ORMATION			Injection	Training:	Office to Ir	nstruct	SP to A	Arrange Tea	aching	
Prescriber Name:			Phone:		Fax	:					
Office Contact:				Email:							
Address:							Ship To:	Patient	: MD C	Office	
IPI#:				Tax ID#:							
Prescription Signature	e:				Dat	e:					
	1 II DI			D 1 200 DI	10 1 0 1 0 1	U DI					